A Novel Ruthenium-Fluvastatin Complex Downregulates SNCG Expression to Modulate Breast Carcinoma Cell Proliferation and Apoptosis via Activating the PI3K/Akt/mTOR/VEGF/MMP9 Pathway

Figure 9

(a) Analysis of cell cycle phase distribution of MCF-7 cells after the treatment with the ruthenium-fluvastatin complex. (b) Analysis of cell cycle phase distribution of MDA-MB-231cells after the treatment with the ruthenium-fluvastatin complex. (c) Quantitative distribution of MCF-7 cells in different phases of the cell cycle. (d) Quantitative distribution of MDA-MB-231 cells in different phases of the cell cycle. (e) Expression of caspase-3 proteins in MCF-7 cells after 24 hours of treatment with the ruthenium-fluvastatin complex. (f) Expression of caspase-3 proteins in MDA-MB-231 cells after 24 hours of treatment with the ruthenium-fluvastatin complex.

(a)

(b)

(c)

(d)

(e)

(f)